Medical Device Testing And Certification Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Medical Device Testing And Certification Market Trends and Insights

Regulatory tightening under EU MDR and FDA Safer Devices Act

The 2024-2028 MDR transition window obliges every legacy device to re-seek CE marking under 23 General Safety and Performance Requirements, tripling technical-file depth for many manufacturers ec.europa.eu. Concurrently, Section 524B of the Safer Devices Act mandates U.S. pre-market submissions that include Software Bills of Materials and vulnerability management plans, expanding documentation for every connected product. The combined effect triggered a 40% surge in notified-body applications and elongated average review times beyond 24 months, prompting firms to outsource larger validation packages to accredited laboratories.

Rise in AI/ML-enabled devices driving specialized validation needs

The FDA’s public database recorded 882 cleared AI/ML medical devices by May 2024, up 45% year-on-year. Each algorithm demands bias detection, dataset shift analysis, and real-world performance monitoring, tests that exceed classical verification. The EU AI Act, classifying medical AI as “high risk”, further requires lifecycle risk management. Laboratories offering algorithm audit services therefore command premium pricing, and this service line is forecast to become a core revenue pillar of the medical device testing & certification services market over the coming decade.

Growth of home & wearable diagnostics expanding test volumes

Pandemic-era consumer familiarity with rapid antigen kits accelerated adoption of connected glucometers, ECG patches, and multi-analyte wearables. Regulators now insist on usability and human-factor evidence collected outside clinical settings, pushing up test unit counts by nearly 30% annually for high-volume consumer devices. Laboratories capable of running distributed user studies and environmental stress simulations attract continuous business from brands seeking fast global roll-outs, bolstering the medical device testing & certification services market.

Mandatory cybersecurity pre-market submissions

Since October 2023 the FDA refuses 510(k) filings lacking secure-by-design documentation, and connected devices launched without a vulnerability disclosure policy risk import detention. UL 2900 certification pathways have become the de facto benchmark ul.com. Testing houses that invested early in penetration-testing benches report project pipelines filled out to mid-2026, affirming cybersecurity as the fastest-growing revenue niche within the medical device testing & certification services market.

Limited capacity & long lead times at notified bodies

Only 43 notified bodies serve the entire EU under MDR, and application-to-certification ratios exceed 4:1. Average review times rose from 14 months in 2022 to more than 26 months by late-2024. Manufacturers have consequently withdrawn certain low-margin products from the EU, shrinking potential testing volumes and tempering growth in the medical device testing & certification services market.

High testing costs for SMEs & start-ups

Comprehensive biocompatibility, sterility, EMC, and cybersecurity packages push even basic Class II validation bills above USD 500,000, a level that strains venture-backed start-ups. Though the FDA offers reduced 510(k) fees to small businesses, those savings cover only submission costs, not laboratory work. Many SMEs defer launches or pivot to markets with lighter regulations, reducing immediate service demand.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Service Type: Testing services remain foundational while cybersecurity accelerates

Testing services held 55.98% of medical device testing & certification market share in 2025, reflecting their status as the unavoidable regulatory entry ticket for all device classes. Certification services track behind because only EU and UK routes legally require third-party auditing, whereas the U.S. relies more on manufacturer self-attestation. However, as regulators intensify post-market surveillance, inspection & auditing revenues are gaining momentum. 

Cybersecurity and software validation—still statistically nested within testing services—represent the fastest revenue stream, posting 5.03% CAGR on account of the FDA and Health Canada mandates. Laboratories that integrate biological, mechanical, and digital-security benches in one location cut total turn-around time by up to 30%, enabling premium billing and reinforcing competitive moat. Consequently, the medical device testing & certification market is shifting toward bundled, subscription-like quality-assurance contracts that lock in multi-year revenue visibility.

Continued investments in automated sample preparation and high-throughput analytics have trimmed direct labor per report by nearly 10% since 2022, raising operating margins. Certification services, hampered by notified-body scarcity, are forecast to grow at a slower 2.44% but remain indispensable for EU market access, sustaining a defensive revenue floor.

By Device Class: Complexity sweet-spot keeps Class II dominant

Class II devices accounted for 42.78% of the medical device testing & certification market size in 2025 because they balance high unit volumes with stringent evidence requirements. Examples include infusion pumps, powered wheelchairs, and many AI-enabled imaging devices. Under the FDA Predetermined Change Control Plan, developers can revise algorithms without submitting a new 510(k) provided they validate performance boundaries, effectively locking in recurring test spend every time a model updates. Class III devices, though smaller in number, deliver premium fees due to mandatory clinical evidence and sterility assurance levels of 10^−6. Class I volumes continue to migrate toward in-house self-testing, yet the cybersecurity clause is pulling some connected devices into third-party labs. In Vitro Diagnostics (IVDs) remain a distinct growth pocket after the EU IVDR extended transitional deadlines to 2028, sustaining elevated certification backlogs.

Overall, rising software content in mid-risk products keeps the medical device testing & certification services market firmly anchored in the Class II space.

By Testing Type: Sterility maintains scale; cybersecurity drives momentum

Sterility & microbiology testing maintained 36.92% revenue share in 2025, supported by universal applicability across implants, disposables, and combination products. ISO 11737 updates on rapid microbial methods encourage labs to invest in PCR-based platforms that cut time-to-certificate by 2-3 days. Parallelly, cybersecurity testing recorded the most robust growth at 5.83% CAGR, reflecting the legislated pivot toward digitally connected devices. Electrical safety and electromagnetic compatibility (EMC) preserve relevance because 100% of new devices integrate wireless components. Packaging & shelf-life assays enjoy tailwinds from eco-friendly materials that require fresh stability datasets.

Conversely, sterility testing rises at a slower 2.98% but still adds nearly USD 0.6 billion in absolute terms over the forecast span. As laboratories cross-sell digital and microbiological services, average project value increases, improving order book resilience.

Geography Analysis

North America captured 38.42% of the medical device testing & certification services market in 2025, anchored by the FDA’s streamlined 510(k) and Breakthrough Device pathways that catalyze continuous product launches. Domestic laboratories benefit from deep payer systems that fund innovation and from a regulatory environment that explicitly recognizes several voluntary consensus standards, shortening validation cycles. From 2026-2031, the region is set to expand at 3.05% CAGR, slower than the global mean due to maturity.

Asia-Pacific is the clear volume engine, forecast to grow 6.42% annually. China’s updated Medical Device Regulation, effective July 2024, compels local producers to secure third-party biocompatibility and packaging data, driving steady sample inflows to regional labs. India’s Medical Device Rules amendment of 2024 extended third-party audit requirements to additional product categories, adding incremental demand. Foreign players are rapidly opening satellite laboratories in Suzhou, Bangalore, and Kuala Lumpur to capture the rising tide.

Europe suffered near-term drag from notified-body scarcity; however, once capacity normalizes, deferred applications will convert to billable tests, helping the region regain momentum beyond 2027. Latin America and the Middle East & Africa remain nascent but benefit from harmonization initiatives, which require proof of compliance with reference-market standards—typically executed by global lab networks.

Regulatory Landscape

The regulatory environment is being shaped by tighter pre-market and post-market expectations across major jurisdictions, expanding the depth of validation packages device makers outsource to accredited laboratories. In the United States, the FDA continues to formalize requirements that increase evidence generation for usability and software assurance, including final guidance issued in May 2026 on the content of human factors information in medical device marketing submissions, alongside continued enforcement of cybersecurity documentation expectations for connected products.

In Europe, implementation of the EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) continues to stress conformity assessment capacity, keeping timelines and documentation burdens elevated for manufacturers and notified bodies. The European Commission introduced Implementing Regulation (EU) 2026/977 in May 2026 to set uniform quality management and procedural requirements for notified body conformity assessment activities, while MDR-related EUDAMED functionality is progressing toward mandatory manufacturer actions such as uploading Summary of Safety and Clinical Performance (SS(C)P) documentation on required timelines.

Value Chain Analysis

The value chain starts with device developers and component suppliers generating design inputs, risk management files, and supplier qualification records, then moves into pre-compliance testing such as mechanical, electrical/EMC, software, and biological safety screening before regulatory submission. External partners then perform accredited verification and validation, including biocompatibility, sterility and microbiology, packaging and shelf-life, and software and cybersecurity testing, feeding results into technical documentation for CE/UKCA routes and FDA submissions. Certification bodies and EU notified bodies sit downstream for conformity assessment and quality system audits, after which manufacturers maintain post-market surveillance and periodic re-testing as designs, materials, or software change.

Regulatory convergence is increasing the importance of standardized quality systems and traceable data flows across this chain. The FDA Quality Management System Regulation (QMSR), effective February 2, 2026, incorporates ISO 13485:2016 by reference, raising expectations for supplier controls, documentation transparency, and lifecycle quality activities that connect internal development teams with external test laboratories. In parallel, MDR/IVDR conformity assessment and MDCG guidance keep demand high for multi-disciplinary providers that can coordinate laboratory outputs, audit readiness, and cross-jurisdiction technical documentation while navigating notified-body scheduling constraints.

Market Opportunities and Future Outlook

Near-term whitespace is concentrated in laboratories that can combine safety/EMC and wireless validation with software and cybersecurity assurance for connected Class II devices, because manufacturers increasingly prefer bundled engagements that reduce scheduling friction across multiple test types. Capacity investments also provide concrete signals of where demand is pulling: Eurofins MET Laboratories opened a 60,000-square-foot facility in Littleton, Massachusetts in February 2026 with a 10-meter semi-anechoic chamber for safety, EMC, and wireless testing, and Lucideon opened a biocompatibility laboratory in Greenville, South Carolina in May 2026 to consolidate biological safety testing. Such expansions track with higher test volumes from home-use and wearable diagnostics that require electrical safety, wireless performance, and usability evidence alongside classical biological and microbiology work.

Opportunities also link to evolving standards and conformity assessment governance that increase retesting and documentation workloads. The EU introduced Implementing Regulation (EU) 2026/977 in May 2026 to standardize notified-body procedures under MDR/IVDR, and the EU updated harmonized standards lists in June 2026 to incorporate newer technical references, including EN ISO 10993-1:2025. On the standards side, ISO updates in 2026 (including ISO 10993-6:2026 and ISO 10993-7:2026, and ISO 14155:2026) reinforce a more lifecycle-oriented approach to biological evaluation and clinical investigation expectations, which supports demand for consultative test planning, gap assessments against revised endpoints, and faster-turnaround methods to preserve submission timelines amid MDR/IVDR backlogs and the FDA QMSR regime.